CMP Pharma, Inc. secured FDA approval on July 29, 2026 for its generic version of QLONILIK (clonidine hydrochloride), marking a significant step toward capturing market share in the cardiovascular treatment sector. This clearance allows the company to introduce a cost-effective alternative to the branded drug, positioning CMP Pharma to capitalize on increased demand from formulary managers seeking to reduce medication expenses.